← Back to All Filings

Incyte Corp Officer/Director Plans $19.8M Stock Sale Under 10b5-1 Plan

Low SignificanceNovember 10, 2025 at 6:32:35 PM EST

INCYTE CORP

$INCY144CIK: 0000879169

Subscribe to track INCY

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Incyte Corp Officer/Director Plans $19.8M Stock Sale

Company: INCYTE CORP (INCY) Form: 144 | Filed: 2025-11-10 Significance: Low

Insider: HERVE HOPPENOT Title: Officer, Director | Relationship: Officer, Director

Transaction: • Type: Proposed Sale • Shares: 187,500 • Price: ~$105.46 • Value: $19,773,454 • Owned After: Not Disclosed

Key Insight: An Officer and Director filed a notice of proposed sale for shares valued at nearly $20M. The sale is planned under a pre-arranged 10b5-1 trading plan adopted in August 2025. While large in absolute terms, the sale represents less than 0.1% of the company's market cap and shares outstanding, indicating low materiality.

Market Context: The shares were acquired via vested RSUs and PSUs between 2017 and 2022. Planned sales by executives are common for liquidity and diversification and are not necessarily indicative of a change in outlook.

Comprehensive Analysis

SEC Filing Analysis: INCYTE CORP (INCY)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: An Officer and Director of Incyte Corp has filed a notice of proposed sale for approximately $19.8 million worth of common stock under a pre-arranged 10b5-1 trading plan.
  • Market Impact: The transaction is not considered material, representing less than 0.1% of the company's market capitalization and shares outstanding.

Company Information

FieldValue
CompanyINCYTE CORP
Ticker SymbolINCY
CIK0000879169
IndustryCommercial Physical & Biological Research

Insider Information

FieldValue
NameHERVE HOPPENOT
CIK0001596492
Title/PositionOfficer, Director
RelationshipOfficer, Director

Transaction Details

FieldValue
Form Type144
Transaction Date2025-11-10 (Approximate Sale Date)
Transaction CodeNot Applicable
Security TypeCommon Stock
Shares Involved187,500
Price Per Share~$105.46 (Aggregate Market Value / Shares)
Total Value$19,773,454.19
Shares Owned AfterNot Disclosed
Ownership TypeNot Disclosed

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$19,773,454.19
% of Market Cap0.095%
Shares Transacted187,500
% of Shares Outstanding0.096%
Post-Transaction OwnershipNot Disclosed
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: For a company with a market capitalization of $20.81 billion, this ~$19.8 million transaction is minor and unlikely to have a market impact.
  • Transaction Significance: The sale represents a very small fraction (under 0.1%) of both the company's market value and its total shares outstanding, placing it in the 'Low' significance category. Such sales are routine for executives at large-cap companies.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The sale is conducted under a 10b5-1 trading plan adopted on August 11, 2025, which severs the link between the sale and any potential non-public information the insider may have at the time of the trade. The size of the sale is immaterial relative to the company's scale.

Volume & Sentiment

  • Expected Volume Impact: Minimal. The number of shares is small compared to typical daily trading volume for a company of this size.
  • Sentiment Indicator: Neutral. Pre-planned sales by executives to diversify assets or for liquidity are common and generally not viewed as a bearish signal, especially when the shares originate from long-term compensation plans.

Additional Context

Transaction Notes

  • Special Circumstances: The filing indicates the sale is planned under a 10b5-1 trading plan. The remarks state the shares were acquired through the vesting of restricted stock units (RSUs) and performance share units (PSUs) from 2017 to 2022, suggesting the sale is for realizing compensation.
Topics:#SECFiling#InsiderTrading#INCY#Incyte#Form144#StockSale#ExecutiveTrade#Biotech#Investing#MarketAnalysis

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.